Drugs / paromlimab
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2/3 | NCT07596290 | Jul 2026 → Dec 2028 expected | rectum adenocarcinoma | Beijing Friendship Hospital | Not yet recruiting | No outcome recorded |
Evidence & citations 1 cited value
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | paromlimab | “Anti-PD-1/CTLA-4 Dual Immunotherapy (paromlimab and Tuvonralimab)” NCT07596290 ↗ |